Lv1
6 积分 2024-03-07 加入
Additive efficacy of a bispecific anti–TNF/IL-6 nanobody compound in translational models of rheumatoid arthritis
1小时前
待确认
Agonists for cytosolic bacterial receptor ALPK1 induce antitumour immunity
19天前
已完结
Innovative pipeline therapeutics in IBD: anti-TL1A and bispecific antibodies
29天前
已完结
IBD Matchmaking: Rational Combination Therapy
1个月前
已完结
TGF-β builds a dual immune barrier in colorectal cancer by impairing T cell recruitment and instructing immunosuppressive SPP1+ macrophages
1个月前
已完结
Destruction of VISTA by TRIM25 ablation in T cells potentiates cancer immunotherapy
1个月前
已完结
Synergistic role of gut-microbial L-ornithine in enhancing ustekinumab efficacy for Crohn’s disease
3个月前
已完结
Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug–Drug Interactions
3个月前
已完结
177a: FIRST-IN-CLASS ORAL TL1A NANOBODY AND LONG-ACTING TL1A/IL-23 BISPECIFIC NANOBODY: NOVEL THERAPIES FOR INFLAMMATORY BOWEL DISEASE
4个月前
已关闭
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
4个月前
已完结
皖公网安备34019202002308
